SBIR Phase II: Physiologic High Throughput Screening of Bioengineered Tissues

Period of Performance: 01/01/2007 - 12/31/2007


Phase 2 SBIR

Recipient Firm

Myomics, Inc.
MYOMICS, INC., 148 West River Street
Providence, RI 02904
Principal Investigator


This Small Business Innovation Research (SBIR) Phase II research develops an innovative high-throughput/high content drug screening platform that utilizes three-dimensional human skeletal muscle tissue constructs that mimic in vivo skeletal muscle to quantify muscle force generation. Significant demands exist for new drugs to treat contractility disorders involving skeletal muscle. Myomics' proposed drug testing platform will contribute to significant reductions in time and costs associated with bringing new drugs to market by discovering drug candidates and eliminating ineffective compounds earlier than currently possible. Unlike existing systems, this approach incorporates biomechanics into drug discovery using mechanical sensors to detect contraction of multiple identical tissue samples over extended time periods. Significant socioeconomic and quality-of-life impacts will result for patients with contractility disorders (sarcopenia, atrophy, or Duchennes muscular dystrophy). While most drug screening protocols test one protein pathway at a time, this